Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
THE MUCIN MARKER, CASA, IN OVARIAN-CANCER
Autore:
MCGUCKIN MA; DEVINE PL;
Indirizzi:
UNIV QUEENSLAND,ROYAL BRISBANE HOSP,DEPT OBSTET & GYNAECOL,CLIN SCI BLDG HERSTON QLD 4029 AUSTRALIA
Titolo Testata:
Tumordiagnostik & Therapie
fascicolo: 1, volume: 16, anno: 1995,
pagine: 1 - 6
SICI:
0722-219X(1995)16:1<1:TMMCIO>2.0.ZU;2-X
Fonte:
ISI
Lingua:
ENG
Soggetto:
POLYMORPHIC EPITHELIAL MUCIN; MONOCLONAL-ANTIBODIES; SERUM; CARCINOMA; BREAST; EXPRESSION; ANTIGENS; ASSAYS;
Keywords:
CANCER-ASSOCIATED SERUM ANTIGEN; OVARIAN CANCER; EPITHELIAL MUCIN; TUMOR MARKER;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
37
Recensione:
Indirizzi per estratti:
Citazione:
M.A. Mcguckin e P.L. Devine, "THE MUCIN MARKER, CASA, IN OVARIAN-CANCER", Tumordiagnostik & Therapie, 16(1), 1995, pp. 1-6

Abstract

The Cancer-associated Serum Antigen (CASA) assay uses two monoclonal antibodies reactive with the core protein of the polymorphic epithelial mucin (MUC1) to measure levels of this molecule in serum. Detection of this mucin using this assay is dependent on the level of glycosylation of this complex molecule. A normal range of CASA levels has been established with smoking, increasing age and chronic respiratory infections increasing basal CASA levels. Because of the independent expression of CASA and CA125 in ovarian cancer, and because CASA is not elevated in most patients with benign adnexal masses, CASA can be used in combination with CA125 to facilitate the discrimination of malignant from benign ovarian disease. Post-operative pre-chemotherapeutic CASA levels appear to more accurately classify the status of residual disease in ovarian cancer resulting in improved prognostic ability of CASA over CA125 at this time. The combination of CASA with CA125 in monitoringfor recurrence of ovarian cancer results in detection of recurrence more than two months before clinical symptoms in 60% of patients. Although this mucin marker appears to generally have a lower sensitivity for ovarian cancer than CA125, when used in combination with CA125 it can enhance the management of patients with this disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/09/20 alle ore 15:22:29